Two cases of extended difficulties after Braxia's psilocybin TRD trial
What the psychedelic industry can learn from these stories
This is a story about how two participants in Braxia’s psilocybin trial for treatment-resistant depression experienced extended difficulties after the trial, which they both blame on the trial conditions, and which they felt were not properly reported in the subsequent results. It’s also a story about how they found each other and we…
